CompletedPhase 2

Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors

Italy43 participantsStarted 2013-05-17

Plain-language summary

This is an open label, single arm, single center, phase 2 study with the use of the antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell tumors who are not cured following first or subsequent chemotherapy lines for metastatic disease, followed by eventual surgery.

Who can participate

Age range18 Years – 75 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male gender. * Confirmation of GCT histology based on pathologic review at Fondazione INT Milan. * Unequivocal progression of measurable disease. * A minimum of 2 and a maximum of 3 platinum-based chemotherapy lines for metastatic disease. * First-line therapy should consist of at least 3 cycles of cisplatin-based chemotherapy. * Prior single, tandem or triple high-dose chemotherapy course given as front-line or salvage therapy is allowed. Exclusion Criteria: * Failure to meet any of the above inclusion criteria. * Concurrent treatment with other cytotoxic drugs or targeted therapies. * Prior radiation therapy within 14 days of trial start.

What they're measuring

Progression Free Survival

Timeframe: 3-months

Trial details

NCT IDNCT01743482

SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-07-27

View on ClinicalTrials.gov More Germ Cell Tumors trials